.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Prof. Dr. Ralf Wagner

Regensburg / DE

University Hospital Regensburg

Weitere Beteiligungen

28.03.2023
Poster
P 299
Ex vivo characterization of IE-1/pp65-expressing adenoviral vectors as potential T cell vaccine candidates for human Cytomegalvirus
Adaptive immunity, Vaccines
28.03.2023
Poster
P 310
Generation and characterization of an Adenoviral vaccine candidate expressing the pentameric complex of human cytomegalovirus
Adaptive immunity, Vaccines
28.03.2023
Poster
P 001
Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
Adaptive immunity
28.03.2023
Poster
P 340
N-glycosylation enzymes are critical for binding and functionality of an HIV-1 broadly neutralizing antibody involved in trogocytotic immune cell communication
Antiviral therapy and resistance, Viral pathogenesis and persistence
28.03.2023
Poster
P 114
Neutralizing Influenza A H1N1 using functionalized DNA-origami nanoshells
Emerging viruses and zoonosis
28.03.2023
Poster
P 235
Heterologous SARS-CoV-2 delta breakthrough infection elicits broader and more durable neutralizing antibody response than (non-breakthrough) infection
Epidemiology and public health, SARS-CoV-2
28.03.2023
Poster
P 135
Higher infection risk among health care workers and lower risk among smokers persistent across SARS-CoV-2 waves – longitudinal results from the population-based TiKoCo seroprevalence study
Epidemiology and public health, SARS-CoV-2
28.03.2023
Poster
P 298
Breakthrough infection with Omicron variants induces persistent and broadly cross-reactive adaptive immunity and associates with protection from reinfection
SARS-CoV-2, Vaccines
28.03.2023
Poster
P 405
Transgene expression knockdown in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene expression across passages
Vaccines, Viral vectors and gene therapy
28.03.2023
Poster
P 402
Towards HERV-H Env protein-based tumor stratification and intervention strategies
Viral transformation and oncogenesis
28.03.2023
16:15 – 16:30 12 Min. 3 Min.
Abstract Talk
O 003
CD32 drives autoantibody-enhanced trogocytosis to facilitate HIV-1 infection of resting CD4 T cells
Host cell factors and modulation, Virus receptors and entry
28.03.2023
16:45 – 17:00 12 Min. 3 Min.
Abstract Talk
O 017
Establishing a virus-free antibody binding inhibition assay using a synthetic Notch receptor
Diagnostic methods and tools, SARS-CoV-2
31.03.2023
11:15 – 11:30 12 Min. 3 Min.
Abstract Talk
O 117
Trivalent MVA-based vaccine candidate induces a potent immune response against Sudan Ebolavirus, Marburg and Lassa fever virus in guinea pigs
Vaccines, Viral vectors and gene therapy